Patent ID: 6498142
Filing Date: 2002-12-24
Classification: A61K,A61P

Abstract:
A method of treatment for a mammal at risk of chronic renal failure comprising:administering to said mammal a therapeutically effective amount of a morphogen, wherein said morphogen comprises a dimeric protein having an amino acid sequence selected from the group consisting of: (i) a sequence having at least 70% amino acid sequence homology with the C-terminal seven-cysteine skeleton of human OP-1, amino acids 38-139 of SEQ ID NO:4; (ii) a sequence having at least a 60% amino acid sequence identity with the C-terminal six-cysteine skeleton of human OP-1, amino acid residues 43-139 of SEQ ID NO:4; (iii) an amino acid sequence variant defined by Generic Sequence 7, SEQ ID NO:1; (iv) an amino acid sequence variant defined by Generic Sequence 8, SEQ ID NO:2; (v) an amino acid substitution variant encoded by a nucleic acid sequence which possesses the ability to hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid sequence encoding the C-terminal seven-cysteine skeleton of OP-1, nucleotides 1036-1341 of SEQ ID NO:15; and (vi) an amino acid substitution variant encoded by a nucleic acid sequence which possesses the ability to hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid sequence encoding the C-terminal seven-cysteine skeleton of OP-2, nucleotides 1390-1695 of SEQ ID NO:19, wherein said morphogen induces endochondral bone formation in an in vivo assay.